Home›Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam›Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam + Amlodipine

Does Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam Interact with Amlodipine?

CDI records a moderate classification for Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and Amlodipine. The stored summary is: Calcium Channel Blockers: e.g., amlodipine diltiazem felodipine nicardipine nifedipine verapamil ↑ calcium channel blockers Caution is warranted and clinical monitoring is recommended upon coadministration of calcium channel blockers with GENVOYA. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Moderate
Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam Class
Cytochrome P450 3A Inhibitor
Amlodipine Class
Dihydropyridine Calcium Channel Blocker
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and your doctor is considering prescribing Amlodipine (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam(Genvoya)+💊 Amlodipine(Tribenzor)

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
Cytochrome P450 3A Inhibitor
Drug B class
Dihydropyridine Calcium Channel Blocker
Source
FDA drug label - elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide

What this means in plain English

Calcium Channel Blockers: e.g., amlodipine diltiazem felodipine nicardipine nifedipine verapamil ↑ calcium channel blockers Caution is warranted and clinical monitoring is recommended upon coadministration of calcium channel blockers with GENVOYA.

About Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and Amlodipine

Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam is a Cytochrome P450 3A Inhibitor, while Amlodipine is a Dihydropyridine Calcium Channel Blocker. You may recognize them by the brand names Genvoya and Tribenzor. Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: FDA drug label - elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Elvitegravir Cobicistat Emtricitabine And Tenofovir Alafenam and Amlodipine against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations